

CALL FOR ROUND TABLE DISCUSSION LEADERS

SUBMISSION DEADLINE: AUGUST 30

Oligonucleotide-Based Therapeutics Conference

OCTOBER 28-30 | BETHESDA NORTH MARRIOTT HOTEL | NORTH BETHESDA, MD



CALL FOR ROUND TABLE DISCUSSION LEADERS

SUBMISSION DEADLINE: AUGUST 30

The organizing committee invites you to propose and volunteer to lead a round table luncheon discussion at the *DIA/FDA Oligonucleotide-Based Therapeutics Conference* to be held **October 28-30, 2019 at the Bethesda North Marriott Hotel, North Bethesda, MD**.

Proposals must be submitted electronically. Select the following online form or copy/paste the link into your web browser:

[Online Submission Form](#)

The deadline for submission is **August 30, 2019** and selections will be made by September 4, 2019. The round table luncheon will be held from 12:00-1:30PM on October 29, 2019.

General guidelines for Round Table Discussions:

- Round table leaders must be a registered attendee
- Round table discussions are being held during a 75-minute luncheon period. The first 15-20 minutes will be allocated to attendees for gathering their lunch and finding their table assignment. The discussion period will be approximately 55-60 minutes.
- Round tables are set up for a maximum of 8-10 participants at each table.
- Participants (attendees) will be asked to complete an online survey in advance of the program to select a table. Those who have not selected a table in advance will be accommodated on-site on a first-come, first-served basis.
- All round table discussions must be noncommercial and scientific in nature and may not be used as a marketing opportunity. Any mention of drug products must be limited to generic names. Please refer to the [DIA Policy Concerning Promotion of Products and Services from the Podium at DIA-Sponsored Activities](#).

When submitting your proposal to lead a Round Table, we will ask for:

1. Your name
2. Contact information
3. The round table discussion title (note this can be tentative)
4. A general theme/topic (examples listed below)
5. A short (2-3 sentences) description of the round table topic with 2-3 questions you plan to discuss

Submission Deadline: August 30

Conference Dates: October 28-30

Questions: Contact Susan Benedetti, MSOL, Project Manager, Meeting Operations, DIA at Susan.Benedetti@DIAglobal.org

Potential Round Table topics may include (but are not limited to) the following list broad topics:

<ul style="list-style-type: none">• 21st Century Cures• PDUFA VI• Immuno/Oncology• Real World Evidence• Global Regulatory Progress• Assay Development and Optimization• Clinical Pharmacology, including Oligonucleotides• ADME<ul style="list-style-type: none">• Clinical Safety• Formulations	<ul style="list-style-type: none">• Impurities• Manufacturing• Nonclinical Efficacy Models• Toxicology, including updates in Oligo-toxicology (clinical and nonclinical)• Novel Mechanisms for Intervention• Novel Oligonucleotide Therapeutics• Oligonucleotide Conjugation and Tissue Targeting• Regulatory Affairs, including Oligonucleotide Regulatory Guidance	<ul style="list-style-type: none">• Oligonucleotide Therapeutics for:<ul style="list-style-type: none">• Rare Diseases• Immunoncology• Metabolic diseases• Neuromuscular Conditions• Targeting and Delivery, including Target Identification Screening• Methods (Discovery)• Translational Experience
--	---	---

Each of these broad topics may have subtopics that you wish to expand upon in your luncheon dialogue-*feel free to be creative*.



CALL FOR ROUND TABLE DISCUSSION LEADERS

SUBMISSION DEADLINE: AUGUST 30

Oligonucleotide-Based Therapeutics Conference

OCTOBER 28-30 | BETHESDA NORTH MARRIOTT HOTEL | NORTH BETHESDA, MD



CALL FOR ROUND TABLE DISCUSSION LEADERS

SUBMISSION DEADLINE: AUGUST 30

If selected, you will be responsible for all costs (e.g., registration, travel, lodging). Also note that the submission form does not allow for updates. If you need to update your submission, please completely resubmit your proposal. There is a field at the end of the form to indicate that it is a resubmission. **Notifications are scheduled for the week of September 4, 2019.**

We look forward to receiving your proposals **by August 30, 2019** and your participation in this conference.

Thank you,

The DIA/FDA Oligonucleotide-Based Therapeutics Conference Program Committee

PROGRAM CO-CHAIRS:

Art A. Levin, PhD

Executive VP Research and Development
Avidity Biosciences

PROGRAM COMMITTEE:

Paul C. Brown, PhD

ODE Associate Director for Pharmacology and Toxicology
OND, CDER, FDA

Daniel Capaldi, PhD

Vice President
Analytical and Process Development
Ionis Pharmaceuticals, Inc.

Xuan Chi, PhD

Pharmacology/Toxicology Reviewer, Division of Cardiovascular
and Renal Products
OND, CDER, FDA

Scott Henry, PhD, DABT

Vice President
Nonclinical Development
Ionis Pharmaceuticals, Inc.

Aimee L. Jackson, PhD

Director of Target Development
miRagen Therapeutics

Arthur M. Krieg, MD

Founder and CSO
Checkmate Pharmaceuticals

Emily J. Place

Pharmacologist, Office of New Drugs
CDER, FDA

Saraswathy V. Nochur, PhD, MSc

Senior Vice President
Regulatory Affairs & QA
Alnylam Pharmaceuticals, Inc.

Louis O'Dea

Executive Vice President, Chief Medical Officer and Head,
Regulatory Affairs
AKCEA Therapeutics

Ramesh Raghavachari, PhD

Chief
Branch I, DPMA1, OLDP, OPQ
CDER, FDA

Eugene Schneider

Vice President
Ionis Pharmaceuticals, Inc.

James Thompson, PhD

Head, CMC Project Management
Moderna Therapeutics

Barry Ticho, DrMed, PhD

CMO
Stoke Therapeutics, Inc

Kim Tyndall

Consultant

James Wild, PhD

Pharmacologist, CDER
FDA